Jannicke Horjen Møller
A5035955800- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Pancreatitis Pathology and Treatment
- Vector-borne infectious diseases
- Genetic factors in colorectal cancer
- Abdominal Surgery and Complications
- Diabetes and associated disorders
- Liver Disease Diagnosis and Treatment
- Viral Infections and Vectors
- Pancreatic and Hepatic Oncology Research
- Insect and Pesticide Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
Stavanger University Hospital
2011-2024
Abstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients COVID-19 were randomised 4 mg once daily or placebo, added standard of care. The primary...
Administration of intravenous fluids remains important in acute pancreatitis, but there is still equipose regarding the amount needed to reduce further organ failure and death. In this paper damaging effects fluid overload are discussed we suggest an approach therapy incorporating recent evidence from randomized controlled trials.
Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in mixed populations of hospitalised participants with COVID-19. Bari-SolidAct is the first trial investigator-initiated, adaptive platform EU-SolidAct, and a multinational, phase 3, randomised, double-blind, placebo-controlled patients confirmed SARS-CoV-2 infection. We aimed to evaluate safety plus standard care adults severe or critical COVID-19.Methods: study was conducted 39 clinical sites...